Product Name

ADCs – Non-Oncology


Previously, the heterogeneous nature of conventional ADCs has generally precluded their uses in diseases outside of oncology.
Our ability to precisely attach a drug at an optimal site on an antibody through a very stable linkage has allowed us to develop ADCs for use in chronic diseases such as inflammation. Our lead ADC for an indication outside cancer is one where we have site-specifically attached a potent immunomodulatory drug to an antibody targeting an antigen on activated T cell subsets. We are exploring this in animal models of inflammation.

Fact Sheet

Data Sheet